Major Funding Announced to Continue the Development of a Vaccine for Leading Disease Affecting Global Poor

Bill & Melinda Gates Foundation to provide Sabin Vaccine Institute with $12 million to fund multiple phase 1 clinical trials and further product development for human hookworm vaccine

WASHINGTON D.C. -- Sabin Vaccine Institute (Sabin) today announced receipt of a two-year, $12 million grant from the Bill & Melinda Gates Foundation to continue development of a vaccine to prevent human hookworm infection, a parasitic disease that affects 600 million people worldwide.

Hookworm infection, most commonly found in sub-Saharan Africa, Southeast Asia and Latin America, is a significant contributor to the global burden of iron-deficiency anemia that disproportionately affects children and women of reproductive age.

To read the full press release, visit the Sabin Vaccine Institute web site.

###
Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people’s health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people—especially those with the fewest resources—have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.

Related Grant

Albert B. Sabin Vaccine Institute, Inc.

ONLINE RESOURCES

Sabin Vaccine Institute

PRESS RELEASES

May 18, 2012Bill Gates’ Statement in Response to G8 Food Security Commitment May 09, 2012Breathalyzers to Test Tuberculosis and Stamped Leaves to Detect Disease in Plants Apr 30, 2012Ashok Alexander Steps Down from India Office Leadership